Skip to main content
EJNMMI Radiopharmacy and Chemistry

Table 2 Comparison of cytotoxicity of radiobioconjugates labeled with Auger electron emitter (125I), β-emitter (198Au) and Auger and β-electron emitter (109Pd/109mAg in vivo generator)

From: Au@109Pd core–shell nanoparticle conjugated to trastuzumab for the therapy of HER2+ cancers: studies on the applicability of 109Pd/109mAg in vivo generator in combined β− auger electron therapy

Radiobioconjugate

T1/2 (days)

Decay mode

Decay numer in 48 h

Radiation emitted

% of metabolic activity in MTS test

Au@Pd125I-trastuzumab

59.49

EC

3.42 × 1012

Auger, low energy gamma

60

198Au-trastuzumab

2.69

β−

2.70 × 1012

β−avg (315 keV)

53

Au@109Pd-trastuzumab

0.57

β−, IT

1.30 × 1012

β−avg (436 keV) + Auger/conversion

10

  1. Activity concentration: 20 MBq/ml, incubation time: 48 h
Back to article page